Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Implementation of new Swiss outpatient reimbursement system postponed until 2026

On June 19, 2024, the Swiss Federal Council granted partial approval to the new outpatient reimbursement system, which consists of the TARDOC catalog of individual service tariffs and the flat-rate system. The systems were developed independently of each other. Currently, the Organization for Outpatient Physician Tariffs AG (OAAT) is responsible for their integration and coordination between various actors. Adjustments were requested to ensure better coordination and adherence to cost neutrality. Consequently, the full implementation of the new outpatient system is now postponed until January 2026.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.